Today's news was very good.
If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb.
CZO would be a very different company , let's hope Gagnon will not f...ck it up. We never know.